Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in relapsed/refractory large B-cell lymphoma

Data from a retrospective, real-world analysis of patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibody (BsAbs) therapy post–CAR T failure suggests that those who experience CAR-T cell failure within the first 3 months after treatment may experience reduced efficacy of BsAbs therapy. In the trial—the results of which were presented during the 2024 American Society of Hematology Annual Meeting—42% of patients responded to BsAbs, but ORR varied based on the immediate (47%) vs. non-immediate (35%) application of BsAbs (p=0.282) and in early (14%), intermediate (25%), and late (44%) relapse post–CAR T-cell therapy (p=0.037).